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Abstract

Our work with hemoglobin-based oxygen carriers (HBOCs) is focused on developing a
hemoglobin (Hb) polymer that can be used as a blood replacement in critical care at an
affordable cost. For medical use, the Hb must be polymeric since cell-free Hb has multiple
adverse side effects when it is not encapsulated in a red blood cell. These include kidney
damage and heme-induced toxicity, which is due to cell-free Hb’s ability to extravasate.
Challenges in making HBOCs, that have been observed in the past, are low protein expression
yields and heterogeneity in polymeric Hb products produced by chemical crosslinking. In
conducting this research, we have two strategies to create a monodisperse high molecular
weight HBOC. The first of these strategies uses sortase-mediated ligation (SML) to introduce a
chemical modification to the Hb monomer, followed by reaction of the modified Hb with a
scaffold molecule that has a specific number of sites that can react with the modified Hb by socalled “click chemistry”. The second strategy involves fusing the gene for Hb to a so-called
“circular tandem repeat protein” (cTRP). The cTRP protein is known to self-assemble into a
tetrameric structure1. Thus, we plan to use the cTRP protein to drive the spontaneous
formation of the polymeric Hb. This work is an important contribution to biomedical research
due to the potential for significant clinical benefits. Clinical trials have been performed with
HBOCs, but the FDA has not yet approved any of them for human therapeutic use due to many
challenges associated with current means of producing Hb polymers2. Our research aims to
address the challenge of making well-defined Hb polymers that can improve the clinical success
of HBOCs for therapeutic use.
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Introduction
Hemoglobin structure. Hemoglobin is a globular 64 kDa metalloprotein that is present in
our red blood cells (RBCs). It is made up of 4 subunits each having one heme group imbedded in
each subunit’s core. Heme is a tetrapyrrole bound to an iron ion in its ferrous form (Fe2+). The
Fe2+ ion not only gives hemoglobin its red color, it also is where Hb binds oxygen reversibly3,4.
Each hemoglobin molecule comprises two α and two β subunits. Figure 1 shows the structure
of a recombinant human hemoglobin, with α subunits in red, β subunits in blue, heme in green,
and Fe2+ in orange. Functionally, the hemoglobin molecule is a dimer of α-β heterodimers. This
gives the Hb its pseudosymmetry, which plays a role in the function and conformational change
of Hb.

Figure 1. Structure of recombinant human hemoglobin (rHb). The α subunits (red) and β
subunits (blue) each contain one heme group (green) that has Fe2+ (orange) bound in the
center. PDB: 1GZX Proteopedia Hemoglobin

Understanding Hemoglobin and its biological function. Hb switches between two major
conformational states as it binds and releases O2 (Figure 2). When Hb is bound to O2 it adopts a
“relaxed” conformation, called the R-state. When O2 is not bound the Hb changes to a “tense”
conformation, called, the T-state5. Oxygen binding displays positive cooperativity; thus, binding
of O2 at one subunit makes it easier for the second, third, and then final oxygen molecule to
bind. The importance of hemoglobin is undeniable, its task of transferring oxygen from our
lungs to our tissues is essential for aerobic organisms to produce the energy they need to live.

Figure 2. Hb’s conformational change for T-state to R-state. The deoxygenated Hb, or the
tense state (T-state) is on the left. The oxygenated Hb, or the relaxed state (R-state) is on the
right. (source: Berg, J. M., Tymoczko, J. L., and Stryer, L. (2002). Biochemistry, 5th Edn. New
York, NY: W. H. Freeman. Section 10.2, Hemoglobin Transports Oxygen Efficiently by Binding
Oxygen Cooperatively. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK22596/)4.
Need for blood alternatives. Currently blood transfusions are the only FDA-approved
method for administering blood. There are many reasons why blood transfusions are necessary.
For developed nations, such as the United States, blood transfusions are used primarily for
patients with cardiovascular disease, transplant surgeries, trauma situations (including the
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battlefield), and various hematological malignancies. Developing nations primarily use blood
transfusions for pregnancy-related complications and severe childhood anemia.
The supply of donated blood is limited by the rate of volunteer donations. For
developed and developing nations there is a disparity in blood donation rates. In Figure 3, the
map shows the difference in whole blood donations per 1,000 population in 2013. The high end
being 56 per 1000 population for the developed nations and the low end being 0.3 per 1000
population for developing nations6,7. In Africa one of the demands for transfusions is severe
childhood anemia, like sickle cell disease. The Democratic Republic of the Congo and Guinea,
indicated in Figure 3 by black arrows, have the highest cases of births with sickle cell anemia per
100,000 births8, yet these are also among the places with the lowest rate of blood donations.

Figure 3. Map of whole blood donations. Map of whole blood donations per 1,000 population
in 20136. Back arrows point to Democratic Republic of the Congo and Guinea. (Adapted from
Global status report on blood safety and availability. World Health Organization (2016).)
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Importance of developing a red blood cell substitute. Even when people donate, the
blood that is given cannot be kept indefinitely due to RBCs steady degradation outside of the
body. Under appropriate storage, the shelf life of RBCs is about 28 days; thus, the need for
blood donations is ongoing9. An additional point of concern is potential for transmission of
blood-borne pathogens, which was first reported in 1982 where an infant developed
transfusion-associated AIDS10. Even if the blood passes all the safety screenings, it still has to be
suitable for the patient’s blood type. Finally, there are some religious groups, such as Jehovah
Witnesses, that don’t allow the receiving of human blood. Despite these hurdles to blood
transfusions, it has been a life-saving procedure for the past 70 years. We aim to expand the
scope of transfusion medicine by improving the availability of a “blood substitute”.
Red blood cell alternatives. Given the issues of safety and supply associated with blood
transfusions, there is a clear need for alternative strategies, including the development of
artificial oxygen carriers (AOCs)2,11. Several candidate AOCs have been studied to find an
alternative to blood transfusions including hemoglobin-based oxygen carriers (HBOCs),
perfluorocarbon-based oxygen carriers (PFOCs), and stem cells (SCs) (Figure 4)2,12,13. A
requirement for these AOCs is reversible O2 binding to allow binding of O2 in an oxygen-rich
environment (e.g., the lungs) and delivery of that O2 in the peripheral tissues. Ideally, the O2
binding affinity measured by the value P50 (partial pressure at which the carrier is 50%
saturated) should be about 26.6 mm Hg (3.5 kPa) which is normal for RBCs in a healthy adult2.
Perfluorocarbons (PFCs), which are synthetically made halogen-substituted compounds,
have primarily carbon and fluorine atoms (Figure 4A)2,12,14. These compounds are not miscible
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with water due to their hydrophobic nature, making PFCs incompatible for intravenous (IV)
transfusion14. Efforts by encapsulating with a biocompatible albumin shell, a nanoscaled

Figure 4. Different candidates for AOC. (A) perfluorocarbon-based oxygen carriers (PFOCs), (B)
hemoglobin-based oxygen carriers (HBOCs), and (C) stem cells (SCs). (source: Ferenz, K. B. &
Steinbicker, A. U. Artificial Oxygen Carriers-Past, Present, and Future-a Review of the Most
Innovative and Clinically Relevant Concepts. J Pharmacol Exp Ther 369, 300–310 (2019).)
PFOC with a perfluorodecalin (PFD) core, have been made to address the insolubility of
PFCs15,16. In Figure 5, PFC emulsions/capsules have a linear trend between O2 partial pressure
and concentration of dissolved O2. Thus, PFOCs only have viable O2 distribution in the hospital
in an environment of 100% O2.17 Compared to the human RBC sigmoidal O2 binding curve,
PFOCs have non-ideal binding characteristics. PFOCs can only bind to O2 under conditions of
very high partial pressure of O2 (pO2) found in an oxygen tent in a hospital. As such, these
compounds have found limited applications, primarily in neonatal intensive care.18
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The other type of AOC exploits the process of stem cell (SC) differentiation into either
RBCs or various target cells in an oxygenated environment (Figure 4C)2. Using SCs will allow for
production of cell based HBOCs without the need for blood donations. With the decline of
blood donations, SCs could play a role in helping to combat this ongoing issue. Though blood
shortages are an ongoing issue, SCs do not resolve all the issues of conventional blood
banking19. Some of the problems with SCs are storage, shipping, shelf life, and expenses19. A big
issue, especially with cost, is the complex growth process of SCs. When growing SCs there is a
need for feeder cells and recombinant transcription factors which is the main contributor to the
high cost19.
Hemoglobin-based oxygen carriers’ pros and cons. The focus of this thesis is on
hemoglobin-based oxygen carriers (HBOCs) which take advantage of the inherent O2-binding
activity of Hb, one of the most studied proteins in the history of biochemistry20. Unlike the
binding curve of PFOCs, the O2 binding curve is sigmoidal reflecting the switch between high
binding affinity (R-state) and lower binding affinity (T-state) conformations (Figure 5). Cell free
Hb also doesn’t discriminate against “blood type” (e.g. A, B, AB or O), meaning in an event that
there is a need for a transfusion it can be done without cross-matching. There are multiple
ways of acquiring RBC-free Hb, the first being resourcing expired human blood or bovine blood
from meat packing industries21. The other one being expression in Escherichia coli, which has
the advantage of being free from mammalian blood pathogens 22. Clinical trials have been
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performed with HBOCs, but the FDA has not approved any for human use due to side effects
observed in the clinic23.

Figure 5. Comparison O2 dissociation curves for human RBCs and different types of RBC
substitutes. Displayed are perfluorocarbon emulsion, O-raffinose polymerized Hb (chemically
polymerized HBOC), αα-crosslinked Hb (a covalently crosslinked HBOC generated by
recombinant technology), human RBCs, and PEG-Hb (an HBOC conjugated with polyethylene
glycol).24
The major side effect of cell free Hb is that it can cause kidney damage as a result of
renal filtration following the dissociation of the a2b2 tetramer into 2 ab heterodimers (Figure
6). These dimers are small enough to be rapidly cleared into the kidneys causing kidney damage
or even kidney failure. This issue can be addressed by chemical crosslinking (e.g., with
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glyceraldehyde)25 or by linking the gene for the two α-globins with a codon for a single glycine
to produce a recombinant human Hb comprising a (di-α)1b2 trimer26 (Figure 6).

Figure 6. Cell free Hb crosslinked. The left is native (uncrosslinked) Hb that dissociates into ab
heterodimers. The right shows an engineered Hb in which the two a subunits are crosslinked by
a glycine26.
Another side effect associated with cell-free Hb is vasoactivity which is due
extravasation of Hb through the blood vessel wall and into the space between endothelial cells
and smooth muscle27. In this space, oxy-Hb reacts with nitric oxide (NO), converting the NO to
nitrate and the oxy-Hb (Fe2+) into its oxidized (Fe3+) form, which is also known as
“methemoglobin” (metHb)28. NO is a vasodilator (smooth muscle relaxing factor) and this
action of oxy-Hb reduces the NO concentration in arterial smooth muscle (Figure 7)29 resulting
in an elevation of mean arterial pressure (i.e., hypertension).
Cell-free Hb has many side effects due to its structural instability but crosslinking Hb by
either chemical or protein engineering has been shown to decrease those affects25,30,31. In
Figure 8, the mean arterial blood pressure for a monomeric Hb is compared to crosslinked Hb
with increasing molecular weight. This figure indicates the decrease of mean arterial blood
pressure is correlated with the increase in molecular weight (MW) of the HBOC14. Thus, a higher
MW poly-Hb is an attractive candidate for an HBOC. Lastly, a higher molecular weight HBOC
was shown to have reduced kidney toxicity32.
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Figure 7. Model of oxy-Hb reacting with NO and NO inhibiting smooth muscle relaxation. NO,
in the red circle, signals for smooth muscles to relax, but when cell-free oxy-Hb is present NO
reacts with oxy-Hb turning NO into NO3- and Hb into metHb (shown in brown).

Figure 8. Changes in blood pressure following administration of hemoglobins of different size
to conscious, unrestrained rats. Hemoglobin constructs included mono-Hb (filled triangles,
orange), di-Hb (filled circles, blue), crosslinked tetra-Hb (filled crosses, green), or human serum
albumin (50 mg/mL, filled squares, purple) as the control13.
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Combating the challenges of HBOC. To address these issues, we implemented two
approaches to making higher MW poly-Hb: chemical crosslinking and/or genetic modification.
The chemical crosslinking technique that we exploit uses sortase-mediated ligation (SML) to
introduce site-specific linkage sites on the Hb. The genetic modification involves the fusion of a
self-assembling oligomerization domain, “circular tandem repeat protein” (cTRP) 33, to the Hb.
So, our work focuses on (i) extending and completing work by prior group members
using SML and “click-chemistry”7,12 and (ii) optimizing the expression of rHb-cTRP and
characterization of the resulting polymeric hemoglobin. Many genetic variants of human Hb are
known34; thus, mutations can be introduced that have predictable impact on oxygen binding
affinity1,13. An outstanding challenge in the field is to produce a polymeric Hb of defined size
rather than a mixture of different sized Hb polymers. As mentioned previously the
unincorporated mono-Hb (64 kDa) and smaller poly-Hbs are associated with adverse side
effects, so they must be removed prior to transfusion23,35,36. Our strategies should lead to
polymers of a single size and thereby would address this outstanding problem.
It is also important to keep in mind the economic feasibility of producing our modified
polymeric recombinant Hb. If the expression yield is low, there would be no practical way to
supply the medical field with our product. Expression yield of globins is correlated to the
thermodynamic stability of the globin37; thus, some globin-stabilizing mutations were
introduced to our Hbs. These mutations are β G16A, β H116I, α G15A, and β K82D, which were
reported by Graves et al. and Weickert et al7,38,39. The β K82D mutation also confers O2 binding
affinity to the Hb that is comparable to that of whole blood39.
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Sortase mediated ligation and click chemistry with Hb-LPETG. The first approach to
developing a polymeric recombinant Hb is outlined out in Figure 9. Sortase-mediated ligation
(SML) is used to introduce a chemical modification (a strained cyclooctyne) to the Hb monomer,
followed by reaction of the modified Hb with a scaffold molecule that has a specific number of
sites (bearing reactive azide groups) that can react with the cyclooctyne on the modified Hb by
so-called “click chemistry”40.

Figure 9. Scheme of the 1st strategy to develop a polymeric recombinant Hb. The first step is
an SML reaction followed by two “Click Chemistry” reactions, producing a di-Hb product.
Sortase A (SrtA), from the gram positive bacterium Staphylococcus aureus, is a peptide
ligase that can be used to mediate ligation of proteins. Sortase recognizes the peptide sequence
LPXTG and cleaves between the threonine and glycine (Figure 11). Forming a thioester bond
between the threonine on Hb and cysteine on SrtA. This intermediate then undergoes
nucleophilic attack by the free amine from a glycine. To take advantage of the SML mechanism,
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we synthesized Hb to have an LPETG
motif at the C-terminus of the dialpha
(α-Gly-α) subunit, which we refer to
as “diαHb-LPETG” (Figure 10). A hexaFigure 10. Hb used in the 1st strategy. A novel
histidine tag was added for ease of
recombinant Hb was modified with a single glycine to
link the α subunits. A sortase tag was also added with a
purification as well as 4 stabilizing
hexa-histidine tag on the C-terminus of the di-α
subunit.
mutations (β G16A, β H116I, α G15A, and β K82D)7. The first reaction in this sequence is to
perform an SML with diαHb-LPETG and GGGK-Dibenzocyclooctyne (DBCO), which will
covalently link a DBCO group to the Hb. This DBCO group will be exploited in the next reaction,
which is based on click chemistry.
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Figure 11. SML of Hb. The LPETG motif on the C-terminus of the Hb is recognized by SrtA. SrtA
cleaves between threonine and glycine forming a thioester bond between Hb and SrtA. The box
shows a zoomed in version of the SML final product, a diα-Hb with DBCO attached.
The next step in this strategy is two rounds of click chemistry reactions, or more
specifically, “strain-promoted alkyne−azide cycloaddition” (SPAAC)41. The linker that we are
using to perform the click reactions is an azide-PEG3-azide compound. In the first click reaction
the DBCO group that was just attached to the diαHb-LPETG through SML reacts with one of the
azides on the bifunctional linker (Figure 12). Once the diαHb-DBCO is modified by reaction with
the azide linker the second click reaction is performed by a second addition of diαHb-DBCO
(Figure 10).
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Figure 12. Click reaction of diαHb-DBCO and N3-PEG3-N3 producing diαHb-PEG3-N3
cTRP for making polymeric recombinant Hb. Tandem repeat proteins (TRPs) are made up
of multiple repeated peptide sequences that can be 20 to 40 residues long33. These TRPs come
in or can be engineered to have a variety of structural motifs including α-helical bundles, βsheets, or mixed topologies42. No matter if the TRPs are engineered or naturally occurring they
have very few restrictions on size and length, as well as the ability to assemble into a variety of
conformations42. Several TRPs have been reported to express easily and have high thermal
stability33,42. TRPs self-associate and can be designed to form closed circular or open linear
protein scaffolds35, which prompted us to consider their use in making polymeric recombinant
hemoglobin33.
The cTRP designed by Correnti et al. contains 24 identical subunits and is referred to as
cTRP24 (Figure 13)33. The repeating 33-residue sequences are folded into left-handed bundle
containing two antiparallel α-helices33,42. In Figure 14, cTRPs also have symmetries that range
from 3 up to 12 identical repeats, such as 3, 4, 6, 8, 12 or 24 repeats. The stability of these cTRP
subunits was improved by designing disulfide bonds between subunits. This is done by mutating
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Pro4 on the N-terminal repeat and Ala6 on the C-terminal repeat to cysteines. Also, cTRPs can
be fused to multiple copies of a protein to promote evenly dispersed assembly and symmetry33.

Figure 13. cTRP24 engineered structure. (A) Secondary structure of cTRP with dimensions
shown in Å. (B) A single repeating unit from cTRP24. The 33 amino acid sequence that makes up
the left-handed two-helix bundle33.
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Figure 14. cTRPs containing 3, 4, 6, 8, 12 or 24 repeats33.
For our second strategy, we exploited the use of cTRP’s ability to self-assemble to make
a polymeric recombinant hemoglobin (Figure 15). This approach is outlined in Figure 16, which
shows a diα-Hb attached to a cTRP subdomain which
can spontaneously self-assemble into a complete 24
subunit domain. In this case we are using the cTRP
Figure 15. Hb used in the 2nd strategy. A with 6 repeats (see Figure 14), meaning that there
novel recombinant Hb was modified with
will be four cTRP subdomains that will be covalently
a single glycine to link the α subunits.
cTRP was added with a hexa-histidine tag
linked through disulfide bonds. The product of this
on the C-terminus of the di-α subunit.
spontaneous self-assembly would be a monodisperse polymeric tetra-Hb.
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Figure 16. Scheme of the 2nd strategy to develop a polymeric recombinant Hb.

17

Research Aims
Our goal with hemoglobin-based oxygen carriers (HBOCs) is to develop a hemoglobin (Hb)
polymer that can be used as a blood replacement in critical care at an affordable cost. The main
two strategies that we have used are:
1. Extending and completing work by prior group members8,13 using SML and “click-chemistry”
to modifiy Hb to have a DBCO group that will react with azides on a PEG linker. Work that
was done previously was with a large azide-PEG that had multiple sites for click reactions.
2. Optimizing the expression of rHb-cTRP and characterization of the resulting polymeric
hemoglobin.
With modern protein engineering strategies, such as the use of SrtA, we aim to expand on past
HBOC research. Previous work has been done in this group to develop recombinant-Hbs with
increased molecular weight, through means of protein engineering43. Our strategies should lead
to polymers of a single size and thereby would address the issues of undesirable elevation in
blood pressure, systemic hypertension, and kidney damage44. This thesis describes the
expression, characterization, and modification of diαHb-LPETG by SML and click chemistry. As
well as preliminary data from the attempted expression, purification, and characterization of
rHb-cTRP.
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Materials and Methods
Protein Expression
Hemoglobin expression system: The “Hb-LPETG” expression plasmid encodes a di-a
globin subunit in which a glycine links the two a globin subunits and a stabilizing mutation is
included in each of the α subunits (α G15A). The di-a gene also includes a C-terminal sortase A
recognition site (LPETG) followed by a 6-histidine tag. The Hb b subunit includes three
stabilizing mutations (β G16A, β H116I and β K82D)45. The di-a and b genes were subcloned
into an expression vector derived from the pDLIII13-e plasmid described by Hoffman et al.26.
Sortase A expression system: Professor John Antos provided a pET-28a(+) expression
vector for sortase A from Staphylococcus aureus (residues 60-206) containing a N-terminal
hexahistidine tag, which was obtained from Prof. Hidde Ploegh (Whitehead Institute for
Biomedical Research).
diαHb-LPETG expression. Overnights were made with 10 µL seed-stock containing
diαHb-LPETG in E. coli BL21 (DE3) in 10 mL LB-tetracycline (23 µM tetracycline) and incubated
for 15-17 hours at 37 °C in an incubator-shaker set to 215 RPM. 10 mL of the overnight culture
was then added to 1 liter of TB-tetracycline media. Once the cells grew to an OD600 of 1.4-1.5
they were induced by addition of isopropyl β-thiogalactopyranoside (IPTG) to a final
concentration of 1 mM. 100 mL of 20% glucose was added to each liter as well as 1 mL of 0.22
µm filtered heme solution, prepared by dissolving 0.05 g of hemin in 6 mL of 20 mM NaOH. For
the 4 hours after inoculation, 1 mL of the heme solution was added to each culture every hour.
Cells were harvested after 5 hours of induction by centrifugation at 5,000 x g for 10 min at 4 °C.
The cell pellet was collected and frozen with liquid N2 and stored at -80 °C.
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rHb-cTRP expression. Expression was done as described above for diαHb-LPETG
expression but ampicillin (50 µg/mL) was add instead of tetracycline.
Expression of Sortase A. Overnights were made with 10 µL SrtAstaph seed-stock incubated
in 10 mL LB media and kanamycin (50 µg/mL) for 15-17 hours at 37 °C in an incubator-shaker
set to 215 RPM. 10 mL of overnight cultures were used to inoculate 1 L of LB media and
kanamycin (50 µg/mL). Once the cells grew to an OD600 of ~0.8 they were induced by addition
of IPTG to 1mM final concentration. The induced culture was incubated at 37 °C for 3 hours.
Cells were harvested by centrifugation at 5,000 x g for 10 min at 4 °C and cell pellets were
collected and frozen with liquid N2 and stored at -80 °C.

Protein purification
Cell lysis. For diαHb-LPETG, the cell pellets were thawed and resuspended in lysis buffer
(300 mM NaCl, 20 mM Tri-HCl, pH 8.5, 10 mM imidazole). Resuspended cells were sonicated on
ice with a 1.8 cm diameter horn, power output level of 5-6, and 50% duty cycle (Branson
Instruments, Inc. Sonifier, model 450). The sonication protocol included three cycles of:
sonication for 30 sec followed by a wait of 30 sec before the next cycle. The lysate was
centrifuged at 40,000 x g for 30 min at 4 °C and supernatant was filtered through a 0.45 µm
filter. For SrtAstaph, the cell pellets were resuspended in 20mM Tris, pH 8.0, 150 mM NaCl, 0.5
mM EDTA), then lysozyme was added to a final concentration of 1mg/mL and was incubated at
room temperature for 1 hour on rocking platform. Lysate was clarified as described above. For
rHb-cTRP the cell pellets were resuspended in 17 mM NaCl, 50 mM Tris-HCl, pH 8.5, and the
cells were lysed by sonication as described above for diαHb-LPETG. The lysate was centrifuged
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at 21,000 x g for 20 min at 4 °C and supernatant was adjusted to have a pH between 8.0 – 8.5.
Test samples of 100 µL were taken to determine the maximal concentration of zinc acetate to
be added prior to loading on the IMAC column (see below), with varying final concentration
from 1-5 µM. The samples were centrifuged for 1 min at 14,000 x g in a tabletop centrifuge and
inspected afterwards to see if the pellets were red. The condition that had the highest
concentration of zinc acetate without a red pellet was used. Zinc acetate was added to the
clarified cell lysate and centrifuged again at 40,000 x g for 20 min at 4 °C. The supernatant was
filtered through a 0.45 µm filter.
Immobilized metal ion affinity chromatography (IMAC) of diαHb-LPETG. A 1.5 cm column
was packed with 10 mL GE Healthcare Fast Flow Chelating Sepharose resin and fitted with a
flow adapter attached to a peristaltic pump. The column was washed and charged with 4
column volumes (CV) of 0.2 M NaCl, 0.5 CV of 0.2 M NiSO4, 4 CV of 20 mM NaOAC, 0.5 M NaCl
pH 4, and 5 CV of 0.2 M NaCl. Clarified lysate was loaded onto the column and washed with 4
CV of wash buffer (20 mM Tris-HCl, pH 8.5, 150 mM NaCl, 50 mM imidazole). The protein was
eluted with 20 mM Tris-HCl, pH 8.5, 50 mM NaCl, 300 mM imidazole.
For SrtAstaph the column was washed and charged with 4 CV of 0.2 M NaCl, 0.5 CV of 0.2
M NiSO4, 1 CV 0.2 M NaCl, and 2 CV of wash buffer (20 mM Tris pH 8.0, 150 mM NaCl, and 20
mM imidazole). Clarified lysate was loaded onto the column and washed with 10 CV of wash
buffer and eluted with 2 CV of 20 mM Tris pH 8.0, 150 mM NaCl, and 300 mM imidazole.
IMAC purification of rHb-cTRP: The column was packed with 3 mL GE Healthcare Fast
Flow Chelating Sepharose resin. The column was washed and charged with 5 CV of 0.2 M NaCl,
2 CV of 20 mM Zn(OAc)2, and 5 CV of 0.2 M NaCl. Clarified lysate was loaded onto the column
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and washed with 8 CV of 20 mM Tris-HCl, pH 8.5, 0.5 M NaCl and proteins that were not bound
tightly were washed with 2 CV 250mM Tris-HCl pH 8.5 and 6 CV 20mM Tris-HCl pH 8.5. The rHbcTRP was eluted with 20 mM Tris-HCl, pH 8.5, 15 mM EDTA pH 8.5 and fractions that appeared
red were collected.
Dialysis. Purified diαHb-LPETG underwent buffer exchange with Fisherbrand dialysis
tubing, molecular weight cutoff (MWCO) of 6,000-8,000 Da. Dialysis tubing was filled with the
protein sample and placed in 1 liter of 20 mM Tris-HCl, pH 8.5, for, at 4 °C for 15-24 hours to
remove the imidazole. If a higher concentration was desired, the samples were concentrated
with Amicon Ultra concentrators with 10,000 MWCO. SrtAstaph was dialyzed against 50 mM Tris
pH 8.0, 150 mM NaCl as described above. Aliquots of purified proteins were stored at -80 °C
(note: glycerol was added to the SrtAstaph samples at a final concentration of 10% (v/v)).
Following dialysis, the mass and purity of the protein were verified by LC-MS (Q-TOF, single
quadrupole) and SDS-PAGE analysis, respectively (see below).

Protein Characterization
UV-Vis spectroscopy. UV-visible spectroscopy was executed with a Thermo Scientific
Nanodrop 1000 Spectrophotometer. The concentration of diαHb-LPETG was calculated using
the extinction coefficient of oxy-Hb = 125,000 M-1cm-1 at 415 nm, while SrtAstaph was calculated
using the extinction coefficient = 14,440 M-1cm-1 at 280 nm.
15% SDS-PAGE. Final Hb loading volume (10-15 µL) was calculated using heme
concentration and kept around 4-8 µg. Acrylamide:bisacrylamide (29:1) gels were cast with a
15% (v/v) resolving layer in 375 mM Tris-HCl, pH 8.8, 0.1% (v/v) SDS, 0.1% (v/v) APS, TEMED and
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a 5% (v/v) stacking layer in 125 mM Tris-HCl, pH 6.8, 0.1% (v/v) SDS, 0.1% (v/v) APS, TEMED.
Samples were treated with SDS-PAGE loading dye and loaded along with a lane containing
Thermo Scientific PageRuler Prestained Protein Ladder to follow protein migration.
Electrophoresis was performed at 90 V until the samples were stacked and then 150 V until
samples were 1-2 cm from the bottom of the gel. The gel was removed and placed in a
Coomassie blue protein stain (50% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.1% (w/v)
Coomassie Brilliant Blue R250) for 15-24 hours. Then the gel was removed from the stain and
rinsed with DI water followed by destain solution (1:3:4 glacial acetic acid:methanol:water). A
Bio Rad Gel Doc EZ imager was used to obtain Coomassie-stained gel images.
Protein Mass Spectroscopy. Protein masses were determined using an Advion
expression CMS instrument connected to a Thermo Scientific Dionex Ultimate 3000 HPLC
system. A Phenomenex Aeris 3.6 µm, WIDEPORE C4 200 Å LC column (100 x 2.1 mm) fitted with
a Phenomenex SecurityGuard Analytical Guard cartridge was used for HPLC-MS analysis. The
following HPLC protocol was used at a flow rate of 0.3 mL/min with mobile phases of H2O (0.1%
formic acid) and MeCN (0.1% formic acid): hold 0.0-0.5 min at 10% MeCN, linear gradient 0.58.0 min of 10-90% MeCN, hold 8.0-10.0 min at 90% MeCN, linear gradient 10.0-10.1 of 90-10%
MeCN, re-equilibrate 10.1-12.0 min at 10% MeCN. The electrospray ionization mass
spectrometry (ESI-MS) data was collected using a 500-1800 Da m/Z range. Using MNova
(MestreLab Research, Ver 10.0) average mass spectra were generated from the chromatogram
peaks. The masses and peak volumes were reconstructed using Analyst’s (SCIEX, Ver 1.4)
maximum entropy algorithm.
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Protein masses were also determined using an Agilent 6545XT AdvanceBio Q-TOF
system interfaced with an Agilent 1290 HPLC system. A Phenomenex AerisTM 3.6 mM
WIDEPORE C4 200 Å column (100 x 2.1 mm) was used upstream from the QTOF to get
separation. Flow rate was 0.3 mL/min, H2O (0.1% formic acid) / MeCN (0.1% formic acid),
method: hold 0.0-1.0 min at 10% MeCN, linear gradient 1.0-9.0 min of 10-90% MeCN, hold 9.011.0 min at 90% MeCN, linear gradient 11.0-11.1 min of 90-10% MeCN, re-equilibrate 11.1-15.0
min at 10% MeCN. Protein charge ladders were deconvoluted using Agilent MassHunter
BioConfirm software (ver 10.0).

Synthesis and ligation of GGGK-DBCO
Synthesis of Fmoc-GGGK. Synthesis of Fmoc-GGGK was performed by manual Fmoc solid
phase peptide synthesis (SPPS). 455 mg (0.02 mmol of Fmoc-protected Rink amide MBHA resin
(0.44 mmol/g) was loaded in to a sterile SPE 15 mL reservoir. Resin was washed 3x with 10 mL
N-Methyl-2-pyrrolidone (NMP) and mixed by rocking for 10 min at room temperature.
Deprotection of Fmoc was achieved by 2x treatments with 10 mL of 80:20 NMP/piperidine
solution for 10 min per treatment. Piperidine was removed using 3x pure NMP 10 mL washes
for 5 min per wash. Coupling reactions were performed with 0.60 mmol Fmoc protected amino
acid (Chem-Impex Int’l Inc.), 228 mg (0.60 mmol) 2-(1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU) (Chem-Impex Int’l Inc.), 174 µL (1.0 mmol)
N,N-Diisopropylethylamine (DIPEA) (Chem-Impex Int’l Inc.) dissolved in 6 mL of NMP. The
coupling reaction was incubated for an hour. The presence of free amino groups was monitored
using a Kaiser test. Unreacted reagents were removed by 3 x 10 mL washes with NMP for 5 min
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per wash. To assemble the desired peptide, cycles of Fmoc deprotection, coupling, and washing
were repeated. Peptide cleavage from solid support was achieved by 3 x 10 mL CH2Cl2 washes, 5
min per wash followed by 2 x 5 mL of 95:2.5:2.5 trifluoroacetic acid (TFA):triisopropylsilane
(TIPS):H2O treatments, 30 min per treatment. A rotary evaporator was used to concentrate the
cleaved solution and then slowly added to 35 mL of dry ice-chilled diethyl ether. Precipitated
peptides were collected by centrifugation and dried overnight under vacuum. The peptide mass
was confirmed by LC-ESI-MS ([M+H]+ = 538 amu). The crude Fmoc-GGGK was solubilized in 0.5
mL of NMP (200 mM final concentration).
Synthesis of GGGK-DBCO. Crude Fmoc-GGGK (4.7 mg, 8.7 µmol) was combined with 3
molar equivalents of DIPEA in NMP) and 0.5 molar equivalents of dibenzocyclooctyne-Nhydroxysuccinimidyl ester (DBCO-NHS) (100 µL reaction volume). The reaction was incubated
for 25 min at room temperature and then the Fmoc-GGGK-DBCO mass (826 amu) was
confirmed by LC-ESI-MS using a Phenomenex Kinetex 2.6 µm, WIDEPORE C18 100 Å LC column
(100 x 2.1 mm). Once completed, the reaction was treated with 25 µL of piperidine and
incubated at room temperature for an additional 50 min. The GGGK-DBCO mass (604 amu) was
confirmed by LC-ESI-MS and RP-HPLC (Phenomenex Luna 5 µm C18(2) 100 Å column (250 x 10
mm), Flow rate was 4.0 mL/min, H2O (0.1% formic acid) / MeCN (0.1% formic acid), method:
hold 0.00-2.00 min at 20% MeCN, linear gradient 2.00-6.00 min of 20-40% MeCN, linear
gradient 6.00-10.00 min of 40-50% MeCN, linear gradient 10.00-11.00 min of 50-90% MeCN,
hold 11.00-13.00 min at 90% MeCN, linear gradient 13.00-13.01 min of 90-10% MeCN, reequilibrate 13.01-14.00 min at 20% MeCN).
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The reaction products were purified by RP-HPLC and the mass of purified GGGK-DBCO
was confirmed by LC-ESI-MS and RP-HPLC. Pure GGGK-DBCO was put on a rotary evaporator to
remove formic acid and MeCN, then lyophilized. The lyophilized GGGK-DBCO was stored at -20
°C. Before conducting a sortase-mediated ligation, GGGK-DBCO was dissolved in 5:1 H2O/DMSO
and the concentration of the peptide was estimated by the absorption of DBCO at 309 nm
(extinction coefficient = 12,000 M-1cm-1) of a 10-fold dilution.

Sortase mediated ligation and purification
Sortase mediated ligation (SML). SrtAstaph was used to mediate diαHb-LPETG ligation to
GGGK-DBCO. The aqueous ligation reaction was composed of 50 µM diαHb-LPETG, 100 µM
GGGK-DBCO, 5 µM SrtAstaph, and 1x SrtAstaph buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10
mM CaCl2). Water, buffer, and peptide were combined, vortexed, and centrifuged. The diαHbLPETG was then added with a pipette and mixed by repeated pipetting. Lastly the SrtAstaph was
added in the same manner. The reaction was incubated for 45-60 min at room temperature.
Progress of the reaction was monitored by mass spectrometry on the Advion/Dionex system as
described above.
Purification of diαHb-DBCO. Purification of SML product, diαHb-DBCO, was performed
using IMAC. The IMAC column (3 mL Thermo Scientific HisPur Ni-NTA resin) was prepped by
washing and charging with 4 CV of 0.2 M NaCl, 0.5 CV of 0.2 M NiSO4, 5 CV of 0.2 M NaCl, 10 CV
of loading buffer (20 mM Tris pH 8.0, 150 mM NaCl, 10 mM imidazole). The SML product was
loaded on to the column and washed with 10 CV of loading buffer. The diαHb-DBCO (lacking the
hexahistidine tag) was eluted with low imidazole buffer (20 mM Tris pH 8.0, 150 mM NaCl, 50
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mM imidazole) and diaHb-LPETG (which includes a His-tag) was eluted with a high imidazole
buffer (20 mM Tris pH 8.0, 150 mM NaCl, 250 mM imidazole). Eluent fractions were
characterized as described above by UV-Vis spectrometry, SDS-PAGE, and mass spectrometry.

Crosslinking diαHb-DBCO with Azido-PEG linkers and purification
Click chemistry. Purified SML product, diαHb-DBCO, was reacted with azido-PEG linkers.
Aqueous reactions were performed with a 10- to 100-fold excess of N3-PEG3-N3, over 50 µM
diαHb-DBCO, and 0-10% of cosolvents (DMSO, methanol, MeCN, and t-butanol). The reaction
was incubated at room temperature and monitored from 0-90 min, using LC-ESI-MS as
described above (Advion/Dionex system).
Purified diαHb-PEG3-N3, was reacted with a 50-fold excess of DBCO-PEG4-OH over 50 µM
diαHb-PEG3-N3 and 5% DMSO. The reaction was incubated at room temperature and monitored
from 0-45 min, using LC-ESI-MS.
Size exclusion chromatography (SEC). Further protein purification and removal of excess
N3-PEG3-N3 linkers from click reactions were performed using an Amersham Pharmacia Biotech
Superdex 75 HR 10/30 column on an ÄKTA Explorer chromatography system. Samples were
concentrated to <1 mL and filtered by centrifugation in a tabletop microfuge using Costar SpinX 2.0 mL 0.22 µm cellulose acetate tube filters at 14,000 RPM for 1 minute. The column was
equilibrated with 1 CV water and 1 CV buffer (20 mM Tris-HCl pH 8.5, 150 NaCl). Absorbance at
280 nm was used to monitor eluent. All peaks that appeared red in color were collected and
hemoglobin content was confirmed with UV-Vis spectroscopy.
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Analytical SEC to determine the oligomerization state of the rHb-cTRP was performed on
an ÄKTA Explorer fitted with a HiPrep Sephacryl S-300 HR 16/60 column using the same method
as above.
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Results
1st Strategy: Exploiting sortase-mediated ligation (SML) and “click-chemistry”
Expression, purification, and characterization of Hb-LPETG. The Hb-LPETG was designed
to have a glycine connecting the two α subunits (diαHb), as well as a SrtA recognition site
(LPETG). Following expression optimization trials, it was determined that Hb yield could be
increased by decreasing the induction temperature to 30 °C.
Following initial IMAC purification protocols that used imidazole to elute the Hb-LPETG,
it was found that the Hb-LPETG did not stay in solution when stored at 4 °C for more than a few
days. In addition, the Hb-LPETG stored at -80 °C appeared to precipitate upon thawing.
Previously our lab has purified Hbs lacking hexahistidine tags using a Zn2+ resin and eluted with
EDTA. Since Hb-LPETG is His-tagged we switched to a Ni2+ column and the use of imidazole in
the elution buffer. We hypothesized that the imidazole might be causing the observed
instability of the purified Hb-LPETG and included a dialysis step to remove it prior to storage.
Dialysis did help improve the stability of the Hb-LPETG, though it did degrade over the course of
a week at 4 °C. Due to the multiple modification steps that take multiple days to conduct, and
verify, this was vital to the success of this project.
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IMAC-purified proteins were analyzed by mass spectrometry (LC-Q-TOF) and 15% SDSPAGE (Figures 17,18). The mass spectrum of Hb-LPETG shows two distinct peaks, one at
32359.75 Da for diαHb-LPETG and the other at 15975.47 Da for β-globin. These observed
masses confirmed the expected masses for diαHb-LPETG (MW: 32359.88 Da) and β-globin
(MW: 15975.37 Da). Purity of the sample was indicated in 15% SDS-PAGE, where there were
distinct bands at 32 kDa for diαHb-LPETG and 16 kDa for β-globin (Figure 18A). Since IMAC
purified Hb-LPETG had some smearing on the 15% SDS-PAGE, the sample was purified further
with a Superdex 75 size exclusion column (SEC). Figure 18B shows that further purification
made little to no difference in the purity of Hb-LPETG, so IMAC alone was used for subsequent

Figure 17. Deconvoluted Q-TOF mass
spectrum of Hb-LPETG used in sortasemediated ligation (SML) reactions. diαHbLPETG expected MW: 32359.88 Da and βglobin expected MW: 15975.37 Da.
purifications. From these two analyses it was determined that Hb-LPETG was successfully
expressed and purified, allowing it to be used in the next step, SML.
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Figure 18. 15% SDS-PAGE analysis of Hb-LPETG
purification. (A) Ladder (lane 1) and Hb-LPETG (lane 3)
from IMAC purification. (B) Ladder (lane 1) and Hb-LPETG
(lane 4) from Superdex 75 SEC.
Expression, purification, and characterization of SrtA. The purpose of expressing SrtA is
to obtain the protein reagent needed for the ligation between Hb-LPETG and GGGK-DBCO. The
MS of the purified SrtA has a MW: 17854.0 Da, which is close to the expected MW: 17851.2 Da
(Figure 19A). Two separate bands, on the 15% SDS-PAGE gel, indicated a SrtA dimer at 36 kDa

Figure 18. Mass spectrum (A) and 15% SDS-PAGE (B) analysis of SrtA used in SML. SrtA
expected MW: 17851.2 Da.
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and a SrtA monomer at 18 kDa (Figure 19B). Both of these analyses signified the SrtA was
sufficiently pure and of appropriate MW since SrtA exists as a dimeric protein in vitro and has
been suggested to have more activity than the monomer46.
Design and synthesis of GGGK-DBCO. A peptide containing a glycine at the N-terminus
was needed for the SML of Hb-LPETG to a peptide “nucleophile” displaying the DBCO group.
Prior work in the Antos lab has shown that the GGG motif is a good sequence to display the Nterminal nucleophile and the e-amino group of lysine provides a convenient site for attachment
of the DBCO group using commercially-available reagents. The required peptide, Fmoc-GGGK
was produced by manual solid-peptide synthesis (SPPS) with a Rink amide MBHA resin. Figure
20 illustrates the progression of steps from Fmoc-GGGK to GGGK-DBCO monitored by LC-ESIMS. Once Fmoc-GGGK was cleaved from the solid support it was confirmed by LC-ESI-MS
(Figure 20A). Crude Fmoc-GGGK was then reacted with DBCO-NHS and DIPEA in NMP, which
produced the Fmoc-GGGK-DBCO intermediate (Figure 20B). Removal of the protecting group
(Fmoc) was achieved by addition of piperidine, giving the desired GGGK-DBCO (Figure 20C). This
product was further purified by RP-HPLC to remove any byproducts or impurities.
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Figure 20. Mass spectra and structures of GGGK-DBCO peptide intermediates. (A) Starting
peptide from solid phase Fmoc-GGGK synthesis (expected MW: 538.25 Da – all of these should
be reported as [M+H], so in other words, all the predicted masses should be 1 Da higher). (B)
Fmoc-GGGK-DBCO, from addition of DBCO to Fmoc-GGGK, (expected MW: 825.35 Da). (C)
Desired GGGK-DBCO from removal of Fmoc protecting group (expected MW: 603.28 Da).
Parent ions (M+1) are shown in red boxes
Sortase Mediated Ligation (SML). Prior to starting an SML reaction, the masses of all the
reactants, diαHb-LPETG, SrtA and the peptide GGGK-DBCO, were confirmed by LC-ESI-MS, and
the reaction progress was monitored by LC-ESI-MS. The product of the SML reaction was
purified by IMAC and the fractions containing diαHb-DBCO were analyzed. Figure 21 shows the
MS of purified diαHb-DBCO. The MS identified diαHb-DBCO MS: 32020.0 Da and β-globin MS:
15978.0 Da, which correlate to the expected masses of 32026.5 Da and 15975.4 Da,
respectively. SML product purity was analyzed by 15% SDS-PAGE and revealed two bands for
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diαHb-DBCO and β-globin at the expected values of MW. Indicating that the SML reaction did
function as expected, producing a product that was further used in click chemistry.

Figure 21. Mass spectrum of SLM product, diαHbDBCO. diαHb-DBCO expected MW: 32026.5 Da and βglobin expected MW: 15975.4 Da.

Figure 22 Simple scheme of Figure 9 to develop a polymeric recombinant Hb.
Refer to Figure 9 (page 11)

Click Chemistry. In previous work done in this lab, large PEG-azide linkers (MW ~ 10,000)
were used to attempt to crosslink multiple diαHb-DBCO to one another. This strategy did not
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yield any detectable crosslinked products12. We hypothesized that the long PEG chains might
make the azide functional group less accessible; thus, we purchased diazido-PEG linkers that
contained only 2 or 3 PEG units (Figure 22). With this change to N3-PEG3-N3, we did see the first
evidence of click reactions between diαHb-DBCO and the shorter linker. In Figure 23, a click
reaction with a 100-fold excess of N3-PEG3-N3 over diαHb-DBCO resulted in all the starting Hb
reacting with the PEG linker after 30 min. At the earliest timepoint we could measure (“t=0”,
which is actually 90-120 sec depending on mixing reactants and getting them into a vial for MS
analysis) the click reaction was already nearly complete. After 30 min the reaction was
completed since diαHb-DBCO was not observed and there was a single peak for the product
diαHb-PEG3-N3 (Figure 23). Both masses observed by the LC-ESI-MS were consistent with the
expected masses, since reaction with N3-PEG3-N3 increases the product mass by 200.10 Da.

Figure 23. Click reaction with 100-fold excess of N3-PEG3-N3 over diαHb-DBCO. Starting
material diαHb-DBCO (expected MW: 32026.5 Da) reacted with N3-PEG3-N3 (MW: 200.10 Da)
producing diαHb-PEG3-N3 (expected MW: 32226.6 Da). The leftmost spectrum is the reaction
at “t=0” (see text) and rightmost spectrum shows that the reaction is completed at t=30
mins.
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Following the purification of the diαHb-PEG3-N3 a second click reaction was attempted
between diαHb-DBCO and the purified diαHb-PEG3-N3. SDS-PAGE analysis was conducted on
purified diαHb-DBCO, purified diαHb-PEG3-N3, and the crude products of the 2nd click reaction
(Figure 24). This second click reaction does not show any evidence for the desired crosslinked
diαHb-PEG3-diαHb product. In Figure 24, the 3rd lane is the SML product (diαHb-DBCO) and
shows bands for diαHb-DBCO at 32 kDa and β-globin at 16 kDa as well as several higher MW
bands. Lane 5 is the purified click product (diαHb-PEG3-N3), and shows the expected bands for
diαHb-PEG3-N3 and β-globin. A second band appears between the 26 kDa and 34 kDa markers.
Given the MS data in Figure 23 we do not expect to see unreacted diαHb-DBCO in this purified
product. The reaction mixture for the attempted second click reaction is shown in the 7th lane.
There are no significant differences between lanes 5 and 7 (we would expect a ~ 60 kDa band

Figure 24. SDS-PAGE of SML and click chemistry reaction
products. Ladder (lane 1), SML product diαHb-DBCO (lane 3),
Click product diαHb-PEG3-N3 (lane 5), and 2nd click reaction
(lane 7).
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for the crosslinked diα-PEG3-diα globin), nor was there any evidence for a crosslinked product
by mass analysis. Thus, we conclude that the second click reaction did not succeed.
After we determined that a click reaction occurs with a large excess of PEG linker, we set
out to find reaction conditions that required less added PEG linker. We found that simply
lowering the molar excess of the PEG linker also reduced yields of the desired product (diαHbPEG3-N3). We then explored conditions that included four different organic cosolvents that are
water miscible: dimethyl sulfoxide (DMSO), acetonitrile (MeCN), methanol and t-butanol. In
Figure 25, a click reaction with 40-fold excess N3-PEG3-N3, diαHb-DBCO, and 10% cosolvent was
reacted for 70 min. At the earliest timepoint we could measure (90-120 sec) there was already
evidence of desired product formation. The reaction appeared to be complete after 70 min.
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Figure 25. Click reaction with 40-fold excess N3-PEG3-N3, diαHb-DBCO, and
10% cosolvent: (A) DMSO, (B) MeCN, (C) methanol, or (D) t-butanol. Starting
material diαHb-DBCO (expected MW: 32026.5 Da) reacted with N3-PEG3-N3
(MW: 200.10 Da) producing diαHb-PEG3-N3 (expected MW: 32226.6 Da).
Leftmost spectra are reaction at “t=0” and rightmost spectra are reaction
completed at t=70min.
Given the results shown in Figure 25, we elected to use either DMSO or methanol in
subsequent click reactions. We opted for DMSO as it is present in medical formulations due to
its low toxicity and its ability to solubilize drugs. Even when human peripheral blood
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mononuclear cells (PBMC) were treated with DMSO 10% (v/v) concentration it did not change
the culture’s viability47. Methanol was also chosen since, in Figure 25C, it appears to promote
the fastest initial reaction time as indicated by the intensity ratio of starting material to
products at “t=0”.
In Figure 26, 10% DMSO or methanol was used as a cosolvent for a click reaction with
20-fold excess N3-PEG3-N3 and diαHb-DBCO. At the earliest timepoint both cosolvent conditions
showed the presence of the diαHb-PEG3-N3 product. After 15 min diαHb-DBCO was still present
in both reactions. The 30 min timepoint indicated that nearly all the starting material was
reacted, and after 45 min there is no change in the diαHb-DBCO signal, indicating that the
reaction is effectively complete. The spectra shown in Figure 26 all have a clear single peak for
product that is roughly 200 mass units higher than the starting Hb.
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Figure 26. Click reaction with 20-fold excess N3-PEG3-N3, diαHb-DBCO, and 10%
cosolvent: (A) DMSO (B) methanol. Starting material diαHb-DBCO (expected MW:
32026.5 Da) reacted with excess N3-PEG3-N3 (MW: 200.10 Da) producing diαHbPEG3-N3 (expected MW: 32226.6 Da). Reaction timepoints are shown in 15 min
increments from t=0 (top spectra) to 45 min (bottom spectra).
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Given these encouraging results, we then repeated the reactions with 5% cosolvent.
Figure 27 displays the LC-ESI-MS of a click reaction with 20-fold excess N3-PEG3-N3, diαHbDBCO, and 5% cosolvent (DMSO or methanol). Like the previous reaction, at the earliest
timepoint the reaction had nearly equal parts diαHb-DBCO and diαHb-PEG3-N3. After 30 min
the reaction shows little change in the intensities of the starting materials and product peaks.
When we tried similar reactions (i.e., 20-fold excess N3-PEG3-N3) with cosolvent levels lower
than 5% there remained significant levels of unreacted diαHb-DBCO (e.g., see Figure 12). Also,
any reactions with 5% cosolvent and a concentration of N3-PEG3-N3 lower than 20-fold excess
did not react completely.
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Figure 27. Click reaction with 20-fold excess N3-PEG3-N3, diαHb-DBCO, and 5%
cosolvent: (A) DMSO (B) methanol. Starting material diαHb-DBCO (expected MW:
32026.5 Da) reacted with excess N3-PEG3-N3 (MW: 200.10 Da) producing diαHb-PEG3N3 (expected MW: 32226.6 Da). Reaction time increases in 15 min increments from
t=0 (top spectra) to 45 min (bottom spectra).
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To show the necessity of cosolvent in the click reaction, a click reaction with 20x N3PEG3-N3 and diαHb-DBCO was carried out without cosolvent. The LC-ESI-MS indicated at t=0
there was mostly diαHb-DBCO compared to diαHb-PEG3-N3 (Figure 28). After t=45 min there
remains significant signal for unreacted diαHb-DBCO compared to those reactions with
cosolvent (Figures 25-27).

Figure 28. Click reaction with 20-fold excess N3-PEG3-N3 and diαHb-DBCO. Starting material
diαHb-DBCO (expected MW: 32026.5 Da) reacted with excess N3-PEG3-N3 (MW: 200.10 Da)
producing diαHb-PEG3-N3 (expected MW: 32226.6 Da). From left to right and top to bottom
the reaction time increases in 15 min increments from t=0 to 45 min.

Given the observed improvements in the first click reactions with cosolvent, we then
tried the second click reaction between diαHb-DBCO and diαHb-PEG3-N3 (at a 2:1 ratio) with
DMSO as a cosolvent at 10% or 20% (v/v). SDS-PAGE analysis for these reactions is shown in
Figure 29. Again, we see no differences between the lanes for diαHb-PEG3-N3 (lane 4) and the
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lanes loaded with the products of the second click reactions (lanes 6 and 8). No evidence for a
crosslinked diα-PEG3-diα chain is evident in the SDS-PAGE or MS analysis of these reactions.

Figure 29. SDS-PAGE of SML and click chemistry products.
Ladder (lane 1), SML product diαHb-DBCO (lane 3), Click
product diαHb-PEG3-N3 (lane 4), 2nd Click (lane 6), and 2nd
Click reaction 2:1 diαHb-DBCO: diαHb-PEG3-N3 with 10%
DMSO (lane 6) or 20% DMSO (lane 8).

Since the 2nd click reaction did not result in the formation of diαHb-PEG3-diαHb, we
wanted to establish that the azide group on the diαHb-PEG3-N3 was capable of reacting with a
DBCO reagent. We were able to obtain a small DBCO-containing PEG alcohol (DBCO-PEG4-OH)
from Professor Amanda Murphy to serve as a reporter for the reactivity of the diαHb-PEG3-N3.
We reacted diαHb-PEG3-N3 with a 50-fold excess of DBCO-PEG4-OH in 5% DMSO (Figure 30). At
the earliest timepoint the starting material diαHb-PEG3-N3 was not observed, indicating that it
had already reacted with the DBCO-PEG4-OH producing diαHb-PEG3-DBCO-PEG4-OH. In addition
to the expected mass for the desired product there are two other peaks: one for diαHb-DBCO
(MW: 32030.0 Da), suggesting that not all of the diαHb-DBCO had reacted in the first click
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reaction to produce diαHb-PEG3-N3, and a second peak at 31956.8 Da, which we believe is an
artifact produced by the mass analysis software (31950.8 Da is the double the expected mass
for β-globin).
Thus, we conclude that the azide group on diαHb-PEG3-N3 is capable of reacting with a
small-molecule DBCO reagent; but, we were unable to determine practically useful reaction
conditions to get diαHb-PEG3-N3 to react with diαHb-DBCO to produce the desired crosslinked
oligomeric Hb.

Figure 30. 2nd Click reaction with 50-fold excess DBCO-PEG4-OH, diαHb-PEG3-N3, and
5% DMSO. Starting material diαHb-PEG3-N3 (expected MW: 32226.6 Da) reacted with
excess DBCO-PEG4-OH (MW: 508.61 Da) producing diαHb-PEG3-DBCO-PEG4-OH
(expected MW: 32735.2 Da). From right to left reaction time increases in 15 min
increments from t=0 to 45 min.
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Preliminary results on expression, purification, and characterization of Hb-cTRP. The
gene cassette for Hb-cTRP encodes the same diα and b globin genes used in Hb-LPETG, except
that a gene for a self-assembling “circular tandem repeat protein” (cTRP) is fused to the Cterminus of the diα globin rather than the LPETG sequence. A small number of different
induction temperatures and times were tried in an attempt to increase protein expression
yield. Within this set, we found the optimal yield when the induction temperature was
decreased to 30 °C for 5 hours. Also, it was determined there was little to no difference in yield
when induction was continued overnight at 18 °C compared to the original 5 h induction at 30
°C. Nevertheless, the expression yields for this construct are extremely low and nearly
undetectable (see below).
Both overnight (18 °C) and 5 h (30 °C) induction trials were purified using the Zn2+ IMAC
protocol. The eluted fraction was faintly colored and SDS-PAGE shows that this fraction

Figure 31. SDS-PAGE analysis of rHb-cTRP IMAC purification pool.
Ladder (lane 1), rHb-cTRP from overnight induction (lane 3), and
rHb-cTRP from 5 h induction (lane 4).
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contained mostly contaminants (Figure 31). There are bands that may correspond to diαHbcTRP at 54 kDa and β-globin at 16 kDa.
The samples were pooled and concentrated to a volume of 500µL. The UV-Vis spectrum
of the concentrated sample indicated the presence of oxyhemoglobin due to distinctive
absorbances at 415 nm, 550 nm and 570 nm (Figure 32).
The concentrated IMAC pool was then loaded on a Sephacryl S300 SEC column. Figure
33 is the elution curve from the SEC which shows the greatest concentration of protein eluted
between 65-75 mL. This fraction was the only fraction that showed any hint of red color. The
highest 280 nm absorbance was at ~68 mL which corresponds to the elution volume for a
protein of MW: ~91,000 Da based on our standard curve (Table 1). This corresponds to the
approximate MW of a Hb-cTRP monomer (85 kDa) rather than the desired self-assembled
tetramer of Hb-cTRP (MW of Hb-cTRP tetramer is ~ 340 kDa; Table 2).

Figure 32. UV-Vis spectrum of rHb-cTRP.
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Figure 33. Sephacryl S300 SEC analysis of rHb-cTRP
IMAC pool. The y-axis is 280 nm absorbance (mAU)
and the x-axis is elution volume (mL).

Figure 34. Sephacryl S300 SEC calibration curve.
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Figure 35 is the Q-TOF MS data from the SEC fraction containing the putative rHb-cTRP.
β-globin is present as is a larger MW species with a mass close to that for the diαHb-cTRP chain.
The observed mass of this larger species is ~ 600 amu larger than expected for the diα-cTRP
chain.

Figure 35. Q-TOF mass spectrum of rHb-cTRP
SEC pool. (A) β-globin expected MW: 15975.37
Da (B) diα-cTRP expected MW: 53363.89 Da.
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Discussion/Summary
Our lab has been focused on developing a monodisperse polyhemoglobin (poly-Hb) for
many years. Initially that work was directed at producing a single-chain human Hb that could be
used as a monomer building block to create genes encoding poly-Hbs of defined size; however,
the decreased expression yields for these Hb variants preclude their practical application in
therapeutic development. Thus, we turned to other strategies to generate poly-Hbs including
the two described in this thesis: (1) SML-mediated addition of a DBCO group to Hb, followed by
a click chemistry reaction with an appropriate azide-functionalized linker, and (2) fusion of a
self-assembling oligomerization domain to human Hb. To date, neither of these strategies
appears to be a viable path forward in generating large amounts of monodisperse poly-Hb for
pre-clinical studies; however, significant progress was made in strategy #1 and we have only
just begun to work on strategy #2.
Previous work in our lab had shown that diaHb-DBCO could react with small fluorescent
dyes bearing an azide7,12; however, no reaction between the diaHb-DBCO and higher MW
multifunctional azido-PEG linkers was observed over several attempts12. Thus, a major goal of
my thesis project was to investigate the reasons for this lack of reactivity and find methods to
overcome this barrier to the production of poly-Hb. Given the previous success reacting HbDBCO with small-molecule azides, we purchased for this study smaller diazido-PEG linkers
composed of 2 or 3 PEG units with terminal azide groups.
The current study required generation of all the reagents needed for sortase-mediated
ligation (SML): expression and purification of the diaHb-LPETG protein, synthesis and
purification of the GGGK-DBCO sortase “nucleophile”, and expression and purification of
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sortase A (SrtA). All of these reagents were successfully produced and characterized. The mass
spectrum, deconvolved from LC-Q-TOF, of Hb-LPETG was only off by <0.10 Da, which indicates
that there is no significant post-translational modifications (e.g., oxidation of Cys or Met;
methylation, etc.) to the diαHb-LPETG subunits. The observed mass of purified SrtA was also
close to expected, being off by <5 Da. Both SDS-PAGE gels for these proteins show the purity of
the samples was greater than 95%. Lastly, the GGGK-DBCO peptide was synthesized in good
yield, purified and confirmed by LC-MS. The SML reaction itself was reproducible with the main
issues being a decrease in SrtA function after three months of being at 4 °C and precipitation of
Hb-LPETG when left in high imidazole.
With diaHb-DBCO in hand, we then began the study of the click reactions between
diaHb-DBCO and excess N3-PEG3-N3. We did observe nearly complete conversion of diaHbDBCO to diaHb-PEG3-N3 using a 100-fold excess of the linker to drive the reaction forward.
However, when a 20-fold excess of N3-PEG3-N3 was used, we did not see complete conversion
of the staring diaHb-DBCO. Observed masses for the diaHb-PEG3-N3 product from LC-ESI-MS
were <20 Da from what was expected (and often much closer). These values are reasonable
given the size of the dia-PEG3-N3 chain, which is near the limit for what the Advion system can
reliably detect.
The addition of a water-miscible organic cosolvent aided in pushing the click reaction
forward at lower (i.e., 20-fold) excess of the diazido-PEG linker. Systematic variation of linker
concentration (50-fold excess to 1:1 vs. diaHb-DBCO) and cosolvent volume (0-10% v/v) in
several small-scale test reactions showed that the optimal condition to achieve complete
conversion of diaHb-DBCO to diaHb-PEG3-N3 was 20-fold excess N3-PEG3-N3 with 5% DMSO or
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methanol. To show that the cosolvent was playing a vital role in the click reaction, another
reaction with 20-fold excess N3-PEG3-N3 with no cosolvent was performed. It was found that
after 45 min, the reaction had starting material (Hb-DBCO) remaining, with no change in the
starting material peak intensity from 45 min to 2 hours (this was true for most click reactions in
our experience). Thus, at this point we had shown that the “first click reaction”, to install the
linker on the Hb, was indeed possible using our diaHb-DBCO.
This desirable outcome was tempered by the lack of observation of crosslinked diaHbPEG3-diaHb when lower (e.g., 1:1 or 1:2) ratios of linker:diaHb-DBCO were mixed. Efficient
crosslinking of the click reagents is a practical necessity for the production of a commerciallyviable HBOC.
Since we could drive the first click reaction forward by using a large excess of the
(relatively) cheaper linker, we set out to achieve the desired crosslinking in two steps as a
proof-of-concept: (1) convert diaHb-DBCO to diaHb-PEG3-N3 in the “first click reaction”, then
(2) convert diaHb-PEG3-N3 to diaHb-PEG3-diaHb in the “second click reaction”. In the first step
we would use excess linker, then purify the product to remove the excess linker and react the
purified diaHb-PEG3-N3 product with a 1:1 or 2:1 excess of diaHb-DBCO in the presence of
cosolvent (10% or 20% v/v DMSO). We did not see any evidence by SDS-PAGE or LC-MS for the
formation of the desired crosslinked diaHb-PEG3-diaHb product.
This disappointing result led us to wonder whether the azide group on the diaHb-PEG3N3 was still reactive. To determine the answer to that question we were fortunate to obtain a
small molecule DBCO reagent from the lab of Professor Murphy (DBCO-PEG4-OH). We then
performed the second click reaction with a 50-fold excess of DBCO-PEG4-OH over diaHb-PEG352

N3 and 5% DMSO, resulting in the production of diaHb-PEG3-DBCO-PEG4-OH with apparent
complete conversion of the diaHb-PEG3-N3 to the expected crosslinked product (based on the
absence of detectable mass for the diaHb-PEG3-N3). This showed that the azide on diaHb-PEG3N3 can react with DBCO on a small molecule when it is present in large excess.
This leads to a couple of unanswered questions. Firstly, does the second click reaction
need a large excess of diaHb-DBCO to produce diaHb-PEG3-diaHb? Or, secondly, is the N3PEG3-N3 linker too short to allow efficient crosslinking of two large molecules like diaHb-DBCO?
The answer to the first question is not of practical value since a viable commercial process
cannot rely on using a large excess of an expensive recombinant protein. The answer to the
second question is of greater value and could be more easily tested by ordering linkers with a
greater number of PEG units. However, the SML-based strategy we have developed already has
issues of concern for large-scale poly-Hb production due to the need to use a 20-fold excess of
the azide linker.
Our second strategy for developing poly-Hb is based on a fusion of Hb and the selfassembling cTRP, which should spontaneously form a tetrameric structure. The data presented
in this work from this approach come with a disclaimer that these results are based on a very
limited set of experiments and should be considered as a progress report on preliminary
results. Expression of rHb-cTRP was surprisingly low, leading to an IMAC-purified fraction that
was mostly contaminating proteins. This sample showed a faint pink color and yielded a UV-Vis
spectrum that includes three visible peaks characteristic of oxy-hemoglobin. Further
purification of the rHb-cTRP by Sephacryl S300 SEC indicated something with an apparent MW
of ~ 91 kDa co-eluted with a pink color. This mass was closer to the monomeric form of rHb53

cTRP and not close to the expected elution volume for the tetrameric rHb-cTRP at ~ 340 kDa.
Finally, the Q-TOF data indicated the presence of β-globin in the sample as well as a larger
species that might be related to diαHb-cTRP; however, the observed MW for this larger species
is 579.38 Da more than expected.
Moving forward there should be a focus on click chemistry with diαHb-DBCO and PEGazide linkers. Specifically, using different linkers varying in length as well as the number of
reactive azide sites because there is evidence that the azides on the linker are reactive. Also,
there is some promise in using an excess of diαHb-DBCO or diαHb-PEG3-N3 in a 2nd click
reaction. Lastly, even though results from rHb-cTRP strategy were preliminary there was still
evidence of β-globin observed using an LC-Q-TOF. Meaning there is still some progress to be
done with rHb-cTRP.
The work done in this thesis was imperative due to the need for AOCs such as HBOCs.
Blood transfusions, as of now, are the only FDA approved method of administering blood. The
use and need for blood transfusions are diverse and a necessity in the medical field. In this
effort to develop an HBOC we have made advancements to the effort of developing a blood
replacement at an affordable cost, which contributes to our aim to better the biomedical
engineering of administering blood.
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